| ACTRAPID | ABBOTT | INSULIN HUMAN BASE RECOMBINANT | DIABETES MELLITUS |  |
| FORXIGA | ASTRAZENECA | DAPAGLIFLOZIN PROPANEDIOL | DIABETES MELLITUS |  |
| GALVUS MET | NOVARTIS | METFORMIN + VILDAGLIPTIN | DIABETES MELLITUS |  |
| GIBTULIO | LUPIN LIMITED | EMPAGLIFLOZIN | DIABETES MELLITUS |  |
| GLYCOMET-GP | USV | GLIMEPIRIDE + METFORMIN | DIABETES MELLITUS |  |
| ISTAMET | SUN | METFORMIN + SITAGLIPTIN | DIABETES MELLITUS |  |
| JANUMET | MSD PHARMACEUTICA | METFORMIN + SITAGLIPTIN | DIABETES MELLITUS |  |
| JARDIANCE | BOEHRINGER INGELHEM | EMPAGLIFLOZIN | DIABETES MELLITUS |  |
| LANTUS | SANOFI | INSULIN GLARGINE RECOMBINANT | DIABETES MELLITUS |  |
| MIXTARD | ABBOTT | INSULIN HUMAN BASE RECOMBINANT + INSULIN HUMAN ISOPHANE RECOMBINANT | DIABETES MELLITUS |  |
| NOVOMIX | ABBOTT | INSULIN ASPART PROTAMINE CRYSTALLINE RECOMBINANT + INSULIN ASPART RECOMBINANT | DIABETES MELLITUS |  |
| ONDERO | LUPIN LIMITED | LINAGLIPTIN | DIABETES MELLITUS |  |
| RYZODEG | ABBOTT | INSULIN ASPART RECOMBINANT + INSULIN DEGLUDEC RECOMBINANT | DIABETES MELLITUS |  |
| TRAJENTA | BOEHRINGER INGELHAM | LINAGLIPTIN | DIABETES MELLITUS |  |
Pingback: AstraZeneca’s Farxiga fails the global trial > PharmaCampus